Evaluation of Blood Biomarkers as an Indicator of Delayed Neurocognitive Recovery

Evaluation of Blood Biomarkers as an Indicator of Delayed Neurocognitive Recovery After Cardiac Surgery

Delayed neurocognitive recovery is defined as a cognitive decline arising after surgery. In the present study, the authors evaluate the level of D-Amino Acid Oxidase, D-serine and Serine racemase in blood as an indicator of delayed neurocognitive recovery after cardiac surgery.

Study Overview

• Status: Completed
• Conditions: Postoperative Cognitive Dysfunction
• Intervention / Treatment: Diagnostic test: Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood; Diagnostic test: Neurocognitive test; Diagnostic test: Assessment of delirium

• Study Type: Interventional
• Enrollment (Actual): 82
• Phase: Not Applicable

Contacts and Locations

Study Locations

• South Korea
  • Select State/Province
    • Seoul, Select State/Province, South Korea, 07061
      • SMG-SNU Boramae Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients scheduled for elective cardiac surgery

Exclusion Criteria:

• MMSE <24
• History of psychological or neurological diseases
• Illiteracy
• Preoperative delirium
• Vision and hearing impairment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Cardiac surgical patients

Diagnostic test: Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood; Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.; Diagnostic test: Neurocognitive test; Neurocognitive test is performed before surgery and at 7 day after surgery; Diagnostic test: Assessment of delirium; Postoperative delirium is assessed daily during 7 days after surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of concentration of D-Amino Acid Oxidase in blood at 1, 2, and 7 day after surgery	Blood level of D-Amino Acid Oxidase is assessed.	Before surgery and at 1, 2, and 7 day after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Concentration of D-serine in blood	Blood level of D-serine is assessed.	Before surgery and at 1, 2, and 7 day after surgery
Concentration of Serine racemase in blood	Blood level of Serine is assessed.	Before surgery and at 1, 2, and 7 day after surgery
Occurrence of delayed neurocognitive recovery	Neurocognitive assessment	Before surgery and at 7 day after surgery

Collaborators and Investigators

• Sponsor: SMG-SNU Boramae Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): January 6, 2021
• Primary Completion (Actual): October 22, 2025
• Study Completion (Actual): October 29, 2025

Study Registration Dates

• First Submitted: December 11, 2020
• First Submitted That Met QC Criteria: December 21, 2020
• First Posted (Actual): December 22, 2020

Study Record Updates

• Last Update Posted (Actual): January 20, 2026
• Last Update Submitted That Met QC Criteria: January 15, 2026
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Postoperative Complications; Pathologic Processes; Neurocognitive Disorders; Cognition Disorders; Cognitive Dysfunction; Pathological Conditions, Signs and Symptoms; Postoperative Cognitive Complications; Investigative Techniques; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Blood Specimen Collection
• Other Study ID Numbers: 30-2020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No